ALT
Price
$6.23
Change
-$0.55 (-8.11%)
Updated
Jan 14 closing price
Capitalization
443.11M
71 days until earnings call
DNLI
Price
$18.74
Change
-$0.85 (-4.34%)
Updated
Jan 14 closing price
Capitalization
2.7B
47 days until earnings call
Ad is loading...

ALT vs DNLI

Header iconALT vs DNLI Comparison
Open Charts ALT vs DNLIBanner chart's image
Altimmune
Price$6.23
Change-$0.55 (-8.11%)
Volume$3.74M
Capitalization443.11M
Denali Therapeutics
Price$18.74
Change-$0.85 (-4.34%)
Volume$985.57K
Capitalization2.7B
ALT vs DNLI Comparison Chart
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. DNLI commentary
Jan 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Buy and DNLI is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 15, 2025
Stock price -- (ALT: $6.23 vs. DNLI: $18.74)
Brand notoriety: ALT and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 97% vs. DNLI: 98%
Market capitalization -- ALT: $443.11M vs. DNLI: $2.7B
ALT [@Biotechnology] is valued at $443.11M. DNLI’s [@Biotechnology] market capitalization is $2.7B. The market cap for tickers in the [@Biotechnology] industry ranges from $374.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.36B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, DNLI is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 2 TA indicator(s) are bullish while DNLI’s TA Score has 6 bullish TA indicator(s).

  • ALT’s TA Score: 2 bullish, 5 bearish.
  • DNLI’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than ALT.

Price Growth

ALT (@Biotechnology) experienced а -14.77% price change this week, while DNLI (@Biotechnology) price change was -11.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.85%. For the same industry, the average monthly price growth was -2.06%, and the average quarterly price growth was -3.70%.

Reported Earning Dates

ALT is expected to report earnings on May 20, 2025.

DNLI is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-6.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.7B) has a higher market cap than ALT($443M). DNLI YTD gains are higher at: -8.047 vs. ALT (-13.592). ALT has higher annual earnings (EBITDA): -103.19M vs. DNLI (-496.05M). DNLI has more cash in the bank: 837M vs. ALT (139M). ALT has less debt than DNLI: ALT (1.77M) vs DNLI (52.5M). ALT has higher revenues than DNLI: ALT (52K) vs DNLI (0).
ALTDNLIALT / DNLI
Capitalization443M2.7B16%
EBITDA-103.19M-496.05M21%
Gain YTD-13.592-8.047169%
P/E RatioN/AN/A-
Revenue52K0-
Total Cash139M837M17%
Total Debt1.77M52.5M3%
FUNDAMENTALS RATINGS
ALT vs DNLI: Fundamental Ratings
ALT
DNLI
OUTLOOK RATING
1..100
547
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
8098
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
8664
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
30n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNLI's Valuation (94) in the Biotechnology industry is in the same range as ALT (97) in the Miscellaneous Commercial Services industry. This means that DNLI’s stock grew similarly to ALT’s over the last 12 months.

ALT's Profit vs Risk Rating (80) in the Miscellaneous Commercial Services industry is in the same range as DNLI (98) in the Biotechnology industry. This means that ALT’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (95) in the Biotechnology industry is in the same range as ALT (98) in the Miscellaneous Commercial Services industry. This means that DNLI’s stock grew similarly to ALT’s over the last 12 months.

DNLI's Price Growth Rating (64) in the Biotechnology industry is in the same range as ALT (86) in the Miscellaneous Commercial Services industry. This means that DNLI’s stock grew similarly to ALT’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that DNLI’s stock grew similarly to ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTDNLI
RSI
ODDS (%)
N/A
Bullish Trend 8 days ago
90%
Stochastic
ODDS (%)
N/A
Bullish Trend 8 days ago
81%
Momentum
ODDS (%)
Bearish Trend 8 days ago
87%
Bullish Trend 8 days ago
80%
MACD
ODDS (%)
N/A
Bullish Trend 8 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 8 days ago
85%
Bullish Trend 8 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 8 days ago
88%
Bearish Trend 8 days ago
85%
Advances
ODDS (%)
Bullish Trend 8 days ago
85%
Bullish Trend 8 days ago
79%
Declines
ODDS (%)
Bearish Trend 14 days ago
88%
Bearish Trend 17 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 8 days ago
83%
Bullish Trend 8 days ago
88%
Aroon
ODDS (%)
Bearish Trend 8 days ago
89%
Bearish Trend 8 days ago
83%
View a ticker or compare two or three
Ad is loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TSCWX18.410.21
+1.15%
Nuveen Quant Small Cap Equity W
JTQIX13.770.10
+0.73%
JHancock ESG International Equity I
VGSCX30.96N/A
N/A
Virtus Duff & Phelps Glb Rl Estt Secs C
CAFFX42.44N/A
N/A
American Funds AMCAP 529F1
ERIFX11.62N/A
N/A
Eaton Vance Balanced R

ALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALT has been loosely correlated with CLDX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALT
1D Price
Change %
ALT100%
-8.11%
CLDX - ALT
46%
Loosely correlated
-5.67%
KRYS - ALT
45%
Loosely correlated
-5.10%
VERV - ALT
42%
Loosely correlated
-4.55%
DNLI - ALT
42%
Loosely correlated
-4.34%
LYEL - ALT
41%
Loosely correlated
-3.23%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-4.34%
BEAM - DNLI
62%
Loosely correlated
-8.77%
LGND - DNLI
54%
Loosely correlated
+2.54%
NTLA - DNLI
52%
Loosely correlated
-3.13%
PRTA - DNLI
51%
Loosely correlated
-3.50%
RCKT - DNLI
51%
Loosely correlated
-2.80%
More